Using MRI to predict treatment response in head and neck cancer
Temporal Diffusion Spectroscopy MRI in Predicting the Comprehensive Positive Score of PD-L1 Expression and the Efficacy of Neoadjuvant Therapy in Head and Neck Squamous Cell Carcinoma
This study is testing if a special type of MRI can help predict how well treatment will work for people with head and neck cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 136 (estimated) |
| Sex | All |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05964595 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the use of temporal diffusion spectroscopy MRI to assess head and neck squamous cell carcinoma (HNSCC). It aims to determine if MRI parameters can predict the comprehensive positive score (CPS) of PD-L1 expression and the effectiveness of neoadjuvant therapy. Participants will undergo various MRI sequences before and after receiving neoadjuvant chemotherapy and immunotherapy. The study does not include a comparison group, focusing solely on the predictive capabilities of the imaging technique.
Who should consider this trial
Good fit: Ideal candidates are patients newly diagnosed with head and neck squamous cell carcinoma who are set to receive neoadjuvant chemotherapy and immunotherapy.
Not a fit: Patients with small tumors (less than 10mm) or those unable to undergo MRI due to contraindications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to tailor neoadjuvant therapy based on individual tumor characteristics, potentially improving patient outcomes.
How similar studies have performed: While the specific approach of temporal diffusion spectroscopy MRI is novel, similar imaging techniques have shown promise in predicting treatment responses in other cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients first diagnosed with head and neck squamous cell carcinoma (HNSCC) by pathological biopsy * Patients proposed to receive 2-3 courses of neoadjuvant chemotherapy and immunotherapy * Patients without contraindications for MRI, such as nonremovable ferromagnetic metal foreign body, claustrophobia, renal insufficiency, and previous history of gadolinium contrast allergy Exclusion Criteria: * Less than 10mm in the maximum diameter of the baseline primary tumor * Poor MRI image quality with obvious metal or motion artifacts * The failure to complete the course of neoadjuvant therapy
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-sen Memorial Hospital — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Xiaohui Duan, Prof.
- Email: duanxh5@mail.sysu.edu.cn
- Phone: 13512762365
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.